People: Dendreon Corp (DNDN.OQ)

DNDN.OQ on NASDAQ Stock Exchange Global Select Market

2.19USD
4:00pm EDT
Price Change (% chg)

$0.02 (+0.92%)
Prev Close
$2.17
Open
$2.18
Day's High
$2.22
Day's Low
$2.14
Volume
462,766
Avg. Vol
514,463
52-wk High
$5.38
52-wk Low
$1.82

Search Stocks

Urdal, David 

Brief Biography

Dr. David L. Urdal, Ph.D. is Director of Dendreon Corporation, since July 1995. Until his retirement in December 2011, he served as Executive Vice President and Chief Scientific Officer since December 2010, and previously served as Chief Scientific Officer and director since joining the Company in July 1995. He also served as Vice Chair of the Company’s Board of Directors from 1995 to June 2004, as Executive Vice President from January 1999 through December 2000, as the Company’s President from January 2001 to December 2003, and as Senior Vice President since June 2004. From 1982 until July 1995, Dr. Urdal held various positions with Immunex Corporation, a biotechnology company, including President of Immunex Manufacturing Corporation, Vice President and Director of Development, and head of the departments of biochemistry and membrane biochemistry. Dr. Urdal serves as a director of VLST, a biotechnology company and previously served as a director of ORE Pharmaceuticals, Inc., a pharmaceutical drug repositioning and development company, from 2007 until 2010. Dr. Urdal received a B.S. in zoology, a M.S. in Public Health and a Ph.D. in Biochemical Oncology from the University of Washington.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
599,099 -- 598,662 1,589,610

Options Compensation

  Quantity Market Value
Exercisable 362,709 50,623.00
Unexercisable 32,291 1,077.00
Exercised 325,467 4,382,010.00
Search Stocks